Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

2.

Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast.

Torphy TJ, Stadel JM, Burman M, Cieslinski LB, McLaughlin MM, White JR, Livi GP.

J Biol Chem. 1992 Jan 25;267(3):1798-804.

3.

Cloning and expression of cDNA for a human low-Km, rolipram-sensitive cyclic AMP phosphodiesterase.

Livi GP, Kmetz P, McHale MM, Cieslinski LB, Sathe GM, Taylor DP, Davis RL, Torphy TJ, Balcarek JM.

Mol Cell Biol. 1990 Jun;10(6):2678-86.

4.
6.
7.

Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase.

Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB.

Biochem Biophys Res Commun. 1998 May 29;246(3):570-7.

PMID:
9618252
8.

Human phosphodiesterase 4A: characterization of full-length and truncated enzymes expressed in COS cells.

Owens RJ, Catterall C, Batty D, Jappy J, Russell A, Smith B, O'Connell J, Perry MJ.

Biochem J. 1997 Aug 15;326 ( Pt 1):53-60.

9.

Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae.

Michaeli T, Bloom TJ, Martins T, Loughney K, Ferguson K, Riggs M, Rodgers L, Beavo JA, Wigler M.

J Biol Chem. 1993 Jun 15;268(17):12925-32.

10.

Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.

Souness JE, Maslen C, Webber S, Foster M, Raeburn D, Palfreyman MN, Ashton MJ, Karlsson JA.

Br J Pharmacol. 1995 May;115(1):39-46.

11.
12.

Detailed characterization of a purified type 4 phosphodiesterase, HSPDE4B2B: differentiation of high- and low-affinity (R)-rolipram binding.

Rocque WJ, Holmes WD, Patel IR, Dougherty RW, Ittoop O, Overton L, Hoffman CR, Wisely GB, Willard DH, Luther MA.

Protein Expr Purif. 1997 Mar;9(2):191-202.

PMID:
9056484
14.
15.

Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.

Jacobitz S, McLaughlin MM, Livi GP, Burman M, Torphy TJ.

Mol Pharmacol. 1996 Oct;50(4):891-9.

PMID:
8863835
16.

Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase.

Gardner C, Robas N, Cawkill D, Fidock M.

Biochem Biophys Res Commun. 2000 May 27;272(1):186-92.

PMID:
10872825
18.

Expression and characterization of deletion recombinants of two cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE-3).

He R, Komas N, Ekholm D, Murata T, Taira M, Hockman S, Degerman E, Manganiello VC.

Cell Biochem Biophys. 1998;29(1-2):89-111.

PMID:
9631240
19.
20.

The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family.

Obernolte R, Bhakta S, Alvarez R, Bach C, Zuppan P, Mulkins M, Jarnagin K, Shelton ER.

Gene. 1993 Jul 30;129(2):239-47.

PMID:
8392015

Supplemental Content

Support Center